

Respiratory syncytial virus entry and how to block it

Nature Reviews Microbiology

17, 233-245

DOI: [10.1038/s41579-019-0149-x](https://doi.org/10.1038/s41579-019-0149-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prospects For the Use of Peptides against Respiratory Syncytial Virus. <i>Molecular Biology</i> , 2019, 53, 484-500.	0.4	5
2	Original Antigenic Sin and Respiratory Syncytial Virus Vaccines. <i>Vaccines</i> , 2019, 7, 107.	2.1	12
3	A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences. <i>Pathogens</i> , 2019, 8, 67.	1.2	32
4	Respiratory syncytial virus (RSV): a scourge from infancy to old age. <i>Thorax</i> , 2019, 74, 986-993.	2.7	96
5	Quercetin pentaacetate inhibits in vitro human respiratory syncytial virus adhesion. <i>Virus Research</i> , 2020, 276, 197805.	1.1	40
6	Panel 1: Biotechnology, biomedical engineering and new models of otitis media. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2020, 130, 109833.	0.4	2
7	Updates on immunologic correlates of vaccine-induced protection. <i>Vaccine</i> , 2020, 38, 2250-2257.	1.7	119
8	Towards a unified classification for human respiratory syncytial virus genotypes. <i>Virus Evolution</i> , 2020, 6, veaa052.	2.2	31
9	Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G. <i>Vaccines</i> , 2020, 8, 337.	2.1	5
10	Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies. <i>Journal of Virology</i> , 2020, 94, .	1.5	16
11	IGF1R is an entry receptor for respiratory syncytial virus. <i>Nature</i> , 2020, 583, 615-619.	13.7	84
12	Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors. <i>Virus Research</i> , 2020, 286, 198068.	1.1	50
13	Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition. <i>Viruses</i> , 2020, 12, 342.	1.5	12
14	Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies. <i>Physiological Reviews</i> , 2020, 100, 1527-1594.	13.1	30
15	Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus. <i>Journal of Materials Chemistry B</i> , 2020, 8, 2607-2617.	2.9	19
16	A New Role for CXCL4 in Respiratory Syncytial Virus Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 648-649.	2.5	3
17	RSV Reprograms the CDK9-Brd4 Chromatin Remodeling Complex to Couple Innate Inflammation to Airway Remodeling. <i>Viruses</i> , 2020, 12, 472.	1.5	17
18	Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists. <i>American Journal of Rhinology and Allergy</i> , 2021, 35, 122-131.	1.0	5

#	ARTICLE	IF	CITATIONS
20	Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus. <i>Viruses</i> , 2021, 13, 234.	1.5	33
21	Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response. <i>Scientific Reports</i> , 2021, 11, 3551.	1.6	3
22	The Basicity Makes the Difference: Improved Canavanine-Derived Inhibitors of the Proprotein Convertase Furin. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 426-432.	1.3	11
23	The SWI/SNF-Related, Matrix Associated, Actin-Dependent Regulator of Chromatin A4 Core Complex Represses Respiratory Syncytial Virus-Induced Syncytia Formation and Subepithelial Myofibroblast Transition. <i>Frontiers in Immunology</i> , 2021, 12, 633654.	2.2	12
24	Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Using Murine Models to Understand Human Pathology. <i>Biochemistry (Moscow)</i> , 2021, 86, 290-306.	0.7	5
25	ĐœĐ¼Đ»ĐμĐ°ÑfĐ»ÑÑ€Đ½Ñ«Đμ Đ, Đ°Đ»ĐμÑ,Đ¾ÑÑ‡Đ½Ñ«Đμ Đ¼ĐμÑ...Đ°Đ½Đ,Đ-Đ¼Ñ« Đ;Đ°Ñ,Đ¾Đ³ĐμĐ½ĐμĐ.Đ°Ñ€ĐμÑĐ;Đ,Ñ€Đ		
26	Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10213.	3.9	142
27	Virus-Induced Changes of the Respiratory Tract Environment Promote Secondary Infections With <i>Streptococcus pneumoniae</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 643326.	1.8	39
28	Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication. <i>Virus Research</i> , 2021, 295, 198277.	1.1	10
29	Structural Characterization and Binding Studies of the Ectodomain G Protein of Respiratory Syncytial Virus Reveal the Crucial Role of pH with Possible Implications in Host-Pathogen Interactions. <i>ACS Omega</i> , 2021, 6, 10403-10414.	1.6	3
30	Elucidation of the Host Bronchial Lymph Node miRNA Transcriptome Response to Bovine Respiratory Syncytial Virus. <i>Frontiers in Genetics</i> , 2021, 12, 633125.	1.1	5
31	Analysis of Incidence and Clinical Characteristics of RSV Infection in Hospitalized Children: A Retrospective Study. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 1525-1531.	1.2	3
32	Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
34	The methyltransferase domain of the Respiratory Syncytial Virus L protein catalyzes cap N7 and 2- <i>O</i> -methylation. <i>PLoS Pathogens</i> , 2021, 17, e1009562.	2.1	11
35	Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018. <i>Archives of Virology</i> , 2021, 166, 2407-2418.	0.9	5
37	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus. <i>Npj Vaccines</i> , 2021, 6, 85.	2.9	9
38	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
39	RSV neutralization assays - Use in immune response assessment. <i>Vaccine</i> , 2021, 39, 4591-4597.	1.7	11

#	ARTICLE	IF	CITATIONS
40	Inhibition of Autophagy Does Not Affect Innate Cytokine Production in Human Lung Epithelial Cells During Respiratory Syncytial Virus Infection. <i>Viral Immunology</i> , 2021, 34, 421-426.	0.6	3
41	Progress in Traditional Chinese Medicine Against Respiratory Viruses: A Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 743623.	1.6	11
42	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021, 12, 5125.	5.8	16
43	Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein. <i>Journal of Virology</i> , 2021, 95, e0048521.	1.5	7
44	Targeting the membrane fusion event of human respiratory syncytial virus with rationally designed β -helical hairpin traps. <i>Life Sciences</i> , 2021, 280, 119695.	2.0	4
45	Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates. <i>Viruses</i> , 2021, 13, 1942.	1.5	10
46	Cellular Immunotherapy and the Lung. <i>Vaccines</i> , 2021, 9, 1018.	2.1	5
47	A morphological transformation in respiratory syncytial virus leads to enhanced complement deposition. <i>ELife</i> , 2021, 10, .	2.8	4
48	The role of Nrf2 in autoimmunity and infectious disease: Therapeutic possibilities. <i>Advances in Pharmacology</i> , 2021, 91, 61-110.	1.2	6
50	Antiviral Drug Targets of Single-Stranded RNA Viruses Causing Chronic Human Diseases. <i>Current Drug Targets</i> , 2020, 21, 105-124.	1.0	18
51	Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs [®] 7630 in SARS-CoV-2-Infected Human Lung Cells. <i>Frontiers in Pharmacology</i> , 2021, 12, 757666.	1.6	23
53	Approaching the End of the Era of Uncontrolled Respiratory Syncytial Virus Disease. <i>Journal of Infectious Diseases</i> , 2021, 223, 737-739.	1.9	2
54	RCSB Protein Data Bank resources for structure-facilitated design of mRNA vaccines for existing and emerging viral pathogens. <i>Structure</i> , 2022, 30, 55-68.e2.	1.6	10
55	Chapter 1. Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets. <i>RSC Drug Discovery Series</i> , 2021, , 1-27.	0.2	7
56	Antisense Oligonucleotide-Based Therapy of Viral Infections. <i>Pharmaceutics</i> , 2021, 13, 2015.	2.0	26
58	Respiratory Syncytial Virus (RSV) Diseases. , 2022, , .		0
60	Ephedrae Herba and Cinnamomi Cortex interactions with G glycoprotein inhibit respiratory syncytial virus infectivity. <i>Communications Biology</i> , 2022, 5, 94.	2.0	9
61	Structural Characterization of Ectodomain G Protein of Respiratory Syncytial Virus and Its Interaction with Heparan Sulfate: Multi-Spectroscopic and In Silico Studies Elucidating Host-Pathogen Interactions. <i>Molecules</i> , 2021, 26, 7398.	1.7	5

#	ARTICLE	IF	CITATIONS
62	A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-D-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3706-3728.	2.9	8
63	Receptors for Respiratory Syncytial Virus Infection and Host Factors Regulating the Life Cycle of Respiratory Syncytial Virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 858629.	1.8	15
64	Favipiravir in the Battle with Respiratory Viruses. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 2224-2236.	1.1	5
65	Integrated Trinity Test With RPA-CRISPR/Cas12a-Fluorescence for Real-Time Detection of Respiratory Syncytial Virus A or B. <i>Frontiers in Microbiology</i> , 2022, 13, 819931.	1.5	3
66	Recent advances in carbon quantum dots for virus detection, as well as inhibition and treatment of viral infection. <i>Nano Convergence</i> , 2022, 9, 15.	6.3	40
67	Serine proteases in neutrophil extracellular traps exhibit anti-Respiratory Syncytial Virus activity. <i>International Immunopharmacology</i> , 2022, 106, 108573.	1.7	3
68	Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 23-29.	1.9	13
69	The New Face of Berries: A Review of Their Antiviral Properties. <i>Foods</i> , 2022, 11, 102.	1.9	7
70	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5271-5285.	1.1	16
72	RSV Prevention in All Infants: Which Is the Most Preferable Strategy?. <i>Frontiers in Immunology</i> , 2022, 13, 880368.	2.2	50
73	Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 854-857.	1.5	11
74	Development of Azaindole-Based Frameworks as Potential Antiviral Agents and Their Future Perspectives. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6454-6495.	2.9	13
75	Axl Mediates Resistance to Respiratory Syncytial Virus Infection Independent of Cell Attachment. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 227-240.	1.4	3
76	Approaches and materials for endocytosis-independent intracellular delivery of proteins. <i>Biomaterials</i> , 2022, 286, 121567.	5.7	19
78	Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. <i>Viruses</i> , 2022, 14, 1162.	1.5	2
79	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	21.5	68
80	RSV disease in infants and young children: Can we see a brighter future?. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	17
81	Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1400-1428.	5.7	3

#	ARTICLE	IF	CITATIONS
82	Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness. <i>Journal of Infectious Diseases</i> , 2023, 227, 1433-1441.	1.9	12
84	The Multifaceted Roles of Autophagy in Infectious, Obstructive, and Malignant Airway Diseases. <i>Biomedicines</i> , 2022, 10, 1944.	1.4	3
85	Analysis of circulating respiratory syncytial virus A strains in Shanghai, China identified a new and increasingly prevalent lineage within the dominant ON1 genotype. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
86	A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
87	Insights into the Anti-inflammatory and Antiviral Mechanisms of Resveratrol. <i>Mediators of Inflammation</i> , 2022, 2022, 1-11.	1.4	11
88	Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. <i>Biomedicines</i> , 2022, 10, 1861.	1.4	8
89	Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development. <i>Viruses</i> , 2022, 14, 1816.	1.5	4
90	Qingfei oral liquid alleviates RSV-induced lung inflammation by promoting fatty-acid-dependent M1/M2 macrophage polarization via the Akt signaling pathway. <i>Journal of Ethnopharmacology</i> , 2022, 298, 115637.	2.0	4
91	Biophysical studies of the interaction of hRSV Non-Structural 1 protein with natural flavonoids and their acetylated derivatives by spectroscopic techniques and computational simulations. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2022, 283, 121751.	2.0	0
92	The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-phenyl acetamide derivative as a novel inhibitor against human respiratory syncytial virus. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 2598-2604.	2.5	0
93	Modulation of Alveolar Macrophages by Postimmunobiotics: Impact on TLR3-Mediated Antiviral Respiratory Immunity. <i>Cells</i> , 2022, 11, 2986.	1.8	3
94	Clinical and biological consequences of respiratory syncytial virus genetic diversity. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612211280.	1.1	6
95	M1-like, but not M0- or M2-like, macrophages, reduce RSV infection of primary bronchial epithelial cells in a media-dependent fashion. <i>PLoS ONE</i> , 2022, 17, e0276013.	1.1	2
96	Detailed Molecular Interactions between Respiratory Syncytial Virus Fusion Protein and the TLR4/MD-2 Complex In Silico. <i>Viruses</i> , 2022, 14, 2382.	1.5	0
97	RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein. <i>Viruses</i> , 2022, 14, 2396.	1.5	10
99	Development of mRNA vaccines against respiratory syncytial virus (RSV). <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 37-53.	3.2	23
100	The antiviral efficacies of small-molecule inhibitors against respiratory syncytial virus based on the F protein. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 169-179.	1.3	1
101	IL-33 Induces an Antiviral Signature in Mast Cells but Enhances Their Permissiveness for Human Rhinovirus Infection. <i>Viruses</i> , 2022, 14, 2430.	1.5	2

#	ARTICLE	IF	CITATIONS
102	Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	3
104	Protective mechanism of quercetin and its derivatives in viral-induced respiratory illnesses. <i>Egyptian Journal of Bronchology</i> , 2022, 16, .	0.3	2
105	Structure-Property-Activity Relationships in Carbon Dots. <i>Journal of Physical Chemistry B</i> , 2022, 126, 10777-10796.	1.2	8
106	Prophylactic Ribonucleic Acid Vaccines to Combat RNA Viral Infections in Humans. , 0, , .		1
108	Airway Epithelial Cell Junctions as Targets for Pathogens and Antimicrobial Therapy. <i>Pharmaceutics</i> , 2022, 14, 2619.	2.0	8
109	Is There a Role for Immunoregulatory and Antiviral Oligonucleotides Acting in the Extracellular Space? A Review and Hypothesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14593.	1.8	1
110	Gimap5 promoted RSV degradation through interaction with M6PR. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
111	RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
112	Neutralizing and Epitope-Specific Antibodies against Respiratory Syncytial Virus in Maternal and Cord Blood Paired Samples. <i>Viruses</i> , 2022, 14, 2702.	1.5	0
113	Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
114	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. <i>Vaccines</i> , 2023, 11, 51.	2.1	9
115	Biochemistry of the Respiratory Syncytial Virus L Protein Embedding RNA Polymerase and Capping Activities. <i>Viruses</i> , 2023, 15, 341.	1.5	1
116	Real-Time Monitoring of Infectious Disease Outbreaks with a Combination of Google Trends Search Results and the Moving Epidemic Method: A Respiratory Syncytial Virus Case Study. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 75.	0.9	2
117	Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?. <i>Viruses</i> , 2023, 15, 392.	1.5	4
119	Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies. <i>Viruses</i> , 2023, 15, 525.	1.5	2
120	Identification of a DRB3*011:01-restricted CD4+ T cell response against bovine respiratory syncytial virus fusion protein. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
121	Circulation pattern and genetic variation of human respiratory syncytial virus in China during 2008-2021. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
122	A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F. <i>Science China Life Sciences</i> , 2023, 66, 729-742.	2.3	1

#	ARTICLE	IF	CITATIONS
123	Machine learning for the identification of respiratory viral attachment machinery from sequences data. PLoS ONE, 2023, 18, e0281642.	1.1	0
124	Respiratory syncytial virus with ongoing COVID-19: is it an emerging threat?. Annals of Medicine and Surgery, 2023, 85, 67-70.	0.5	7
125	Epidemiology and molecular characteristics of respiratory syncytial virus (RSV) among italian community-dwelling adults, 2021/22 season. BMC Infectious Diseases, 2023, 23, .	1.3	6
126	Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infectious Diseases, The, 2023, 23, 856-866.	4.6	17
127	Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation. Cureus, 2023, , .	0.2	12
129	Semi-Synthesis and Biological Evaluation of 25(R)-26-Acetoxy-3 β ,5 β -Dihydroxycholest-6-One. Marine Drugs, 2023, 21, 191.	2.2	0
130	Immunoinformatics aided approach for predicting potent cytotoxic T cell epitopes of respiratory syncytial virus. Journal of Biomolecular Structure and Dynamics, 0, , 1-13.	2.0	1
131	Interactions of heparin with key glycoproteins of human respiratory syncytial virus. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0
132	Effects of pH alteration on respiratory syncytial virus in human airway epithelial cells. ERJ Open Research, 2023, 9, 00404-2022.	1.1	1
144	Respiratory syncytial virus infection and novel interventions. Nature Reviews Microbiology, 2023, 21, 734-749.	13.6	23
146	Spatial resolution of virus replication: RSV and cytoplasmic inclusion bodies. Advances in Virus Research, 2023, , .	0.9	0